Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841148 · ClinicalTrials.gov registry record · Phase 2
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 7
- Study locations
NCT04841148: Recruiting Phase 2 study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04841148 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 96 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841148, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Primary Outcome
Endpoint: Proportion of subjects in each treatment arm with clearance of DTCs at the end of 6 cycles of therapy.
Conditions Studied
Interventions
- DRUG Palbociclib
- DRUG Avelumab
- DRUG HCQ
Study Locations (7)
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt University - Nashville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
What NCT04841148 shows while recruiting
NCT04841148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Palbociclib is the first listed.
NCT04841148 lists 7 locations in 7 states (District of Columbia, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT04841148 about?
NCT04841148 is a clinical study titled "Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer". This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
What is the current status of trial NCT04841148?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2021-06-01. Estimated completion is 2028-05.
What conditions does trial NCT04841148 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04841148?
The interventions under investigation include: Palbociclib (DRUG), Avelumab (DRUG), HCQ (DRUG).
Who is sponsoring clinical trial NCT04841148?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04841148 being conducted?
This trial has 7 study locations across District of Columbia, Illinois, Indiana, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04841148's enrollment target sits among peer trials
96 604th of 1224 higher than 618 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI